[1] [1] GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017[J]. Lancet, 2018, 392(10159): 1789-858.

[2] [2] VAN RIET E E S, HOES A W, LIMBURG A, et al. Prevalence of unrecognized heart failure in older persons with shortness of breath on exertion[J]. Eur J Heart Fail, 2014, 16(7): 772-777.

[3] [3] CHUGH S S, HAVMOELLER R, NARAYANAN K, et al. Worldwide epidemiology of atrial fibrillation: a global burden of disease 2010 study[J]. Circulation, 2014, 129(8): 837-847.

[4] [4] BORLAUG B A. Evaluation and management of heart failure with preserved ejection fraction[J]. Nat Rev Cardiol, 2020, 17(9): 559-573.

[5] [5] REDDY Y N V, BORLAUG B A, GERSH B J. Management of atrial fibrillation across the spectrum of heart failure with preserved and reduced ejection fraction[J]. Circulation, 2022, 146(6): 339-357.

[6] [6] ICA O, KHAMBOO W, KOTECHA D. Breaking the cycle of heart failure with preserved ejection fraction and atrial fibrillation[J]. Card Fail Rev, 2022, 8: e32.

[8] [8] SOLOMON S D, MCMURRAY J J V, CLAGGETT B, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction[J]. N Engl J Med, 2022, 387(12): 1089-1098.

[9] [9] ANKER S D, BUTLER J, FILIPPATOS G, et al. Empagliflozin in heart failure with a preserved ejection fraction[J]. N Engl J Med, 2021, 385(16): 1451-1461.

[10] [10] KEWCHAROEN J, PRASITLUMKUM N, CHOKESUWATTANASKUL R, et al. Ablation versus medication as initial therapy for paroxysmal atrial fibrillation: an updated meta-analysis of randomized controlled trials[J]. J Arrhythm, 2021, 37(6): 1448-1458.

[11] [11] VAN RIET E E S, HOES A W, WAGENAAR K P, et al. Epidemiology of heart failure: the prevalence of heart failure and ventricular dysfunction in older adults over time. A systematic review[J]. Eur J Heart Fail, 2016, 18(3): 242-252.

[12] [12] BENJAMIN E J, VIRANI S S, CALLAWAY C W, et al. Heart disease and stroke statistics—2018 update: a report from the American Heart Association[J]. Circulation, 2018, 137(12): e67-e492.

[13] [13] JASIC-SZPAK E, MARWICK T H, DONAL E, et al. Prediction of AF in heart failure with preserved ejection fraction: incremental value of left atrial strain[J]. JACC Cardiovasc Imaging, 2021, 14(1): 131-144.

[14] [14] SANTHANAKRISHNAN R, WANG N, LARSON M G, et al. Atrial fibrillation begets heart failure and vice versa: temporal associations and differences in preserved versus reduced ejection fraction[J]. Circulation, 2016, 133(5): 484-492.

[15] [15] MCMURRAY J J V, SOLOMON S D, INZUCCHI S E, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction[J]. N Engl J Med, 2019, 381(21): 1995-2008.

[16] [16] ZELNIKER T A, BONACA M P, FURTADO R H M, et al. Effect of dapagliflozin on atrial fibrillation in patients with type 2 diabetes mellitus: insights from the DECLARE-TIMI 58 trial[J]. Circulation, 2020, 141(15): 1227-1234.

[17] [17] LI D B, LIU Y Y, HIDRU T H, et al. Protective effects of sodium-glucose transporter 2 inhibitors on atrial fibrillation and atrial flutter: a systematic review and meta-analysis of randomized placebo-controlled trials[J]. Front Endocrinol (Lausanne), 2021, 12: 619586.

[18] [18] LI H L, LIP G Y H, FENG Q, et al. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis[J]. Cardiovasc Diabetol, 2021, 20(1): 100.

[19] [19] YILMAZ M, ALTIN C, TEKIN A, et al. Assessment of atrial fibrillation and ventricular arrhythmia risk after bariatric surgery by P wave/QT interval dispersion[J]. Obes Surg, 2018, 28(4): 932-938.